Overview

Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740

Status:
Recruiting
Trial end date:
2022-08-17
Target enrollment:
Participant gender:
Summary
This is a Phase 1, single-site, open-label, fixed sequence crossover study to investigate the effect of coadministration of itraconazole on the pharmacokinetics of CRD-740 in healthy male and female subjects. Subjects will be admitted into the study site on Day -1 and will be confined to the study site until discharge on Day 16. Subjects will receive CRD-740 orally on Days 1 and 10. Itraconazole will be given once daily, orally, on Days 7 through 15.
Phase:
Phase 1
Details
Lead Sponsor:
Cardurion Pharmaceuticals, Inc.
Treatments:
Itraconazole